Targeting HER2 in urothelial carcinoma: from pathway inhibition to antibody-drug conjugates

Multiple HER2-targeted strategies show promise in urothelial cancer, expanding treatment options beyond standard chemotherapy.

What the study was

Journal

Cancer Treat Rev

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.